XML 54 R41.htm IDEA: XBRL DOCUMENT
v3.8.0.1

Collaboration Agreements - Ipsen Collaboration (Details) $ in Millions | 1 Months Ended | 3 Months Ended | 23 Months Ended |
--- | --- | --- | --- | ---
Feb. 29, 2016 USD ($) | Mar. 30, 2018 USD ($) | Mar. 30, 2018 CAD ($) | Dec. 31, 2017 USD ($) | Mar. 31, 2017 USD ($) | Dec. 29, 2017 USD ($) | Dec. 30, 2017 USD ($)
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |
License revenues |  | $ 69,030,000 |  |  | $ 11,214,000 |  |
Net contract asset |  | $ 31,844,000 |  |  |  | $ 9,588,000 | $ 9,588,000
Collaborative Arrangement with Ipsen |  |  |  |  |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |
Upfront payment(s) | $ 210,000,000 |  |  |  |  |  |
Milestone payments earned |  |  |  |  |  | $ 125,000,000 |
Additional milestone achievement | 199,000,000 |  |  |  |  |  |
Contingent cash receipts (up to) | 545,500,000 |  |  |  |  |  |
Research and development arrangement performed for others, reimbursement for costs incurred, percent |  | 35.00% | 35.00% |  |  |  |
Collaboration period to achieve specified levels of commercial performance |  | 10 years | 10 years |  |  |  |
Remaining performance obligation |  | $ 54,000,000 |  |  |  |  |
Net contract asset |  | $ 31,800,000 |  |  |  |  |
Collaborative Arrangement with Ipsen | GlaxoSmithKline |  |  |  |  |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |
Percent of royalty on net sale |  | 3.00% | 3.00% |  |  |  |
Collaborative Arrangement with Ipsen | Initial and Second |  |  |  |  |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |
Royalty tier |  | $ 150,000,000 |  |  |  |  |
Collaborative Arrangement with Ipsen | Initial and Second | Minimum |  |  |  |  |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |
Percent of royalty on net sale |  | 22.00% | 22.00% |  |  |  |
Collaborative Arrangement with Ipsen | Initial and Second | Maximum |  |  |  |  |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |
Percent of royalty on net sale |  | 26.00% | 26.00% |  |  |  |
Collaborative Arrangement with Ipsen | Initial |  |  |  |  |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |
Percent of royalty on net sale |  | 2.00% | 2.00% |  |  |  |
Royalty tier |  | $ 50,000,000 | $ 30.0 |  |  |  |
Collaborative Arrangement with Ipsen | Second |  |  |  |  |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |
Percent of royalty on net sale |  | 12.00% | 12.00% |  |  |  |
Royalty tier |  | $ 100,000,000 |  |  |  |  |
Collaborative Arrangement with Ipsen | HCC Filing |  |  |  |  |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |
Milestone payments earned |  |  |  | $ 10,000,000 |  |  |
Collaborative Arrangement with Ipsen | HCC Acceptance |  |  |  |  |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |
Additional milestone achievement | $ 40,000,000 |  |  |  |  |  |
Collaborative Arrangement with Ipsen | EMA Approval - 1L RCC [Member] |  |  |  |  |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |
Additional milestone achievement |  | 50,000,000 |  |  |  |  |
License revenues |  | $ 45,800,000 |  |  |  |  |

X
- Definition Collaborative Arrangement, Achievement Levels of Commercial Performance, Period + References No definition available. + Details
Name: | exel_CollaborativeArrangementAchievementLevelsofCommercialPerformancePeriod
Namespace Prefix: | exel_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Eligible Payment From Collaboration For Development And Regulatory Milestone Achievement Under Collaborations Agreement + References No definition available. + Details
Name: | exel_EligiblePaymentFromCollaborationForDevelopmentAndRegulatoryMilestoneAchievementUnderCollaborationsAgreement
Namespace Prefix: | exel_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Maximum amount eligible for commercial milestones under collaborations agreement. + References No definition available. + Details
Name: | exel_MaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement
Namespace Prefix: | exel_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Milestone Payments Earned + References No definition available. + Details
Name: | exel_MilestonePaymentsEarned
Namespace Prefix: | exel_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Percent of royalty on net sale. + References No definition available. + Details
Name: | exel_PercentOfRoyaltyOnNetSale
Namespace Prefix: | exel_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Research and Development Arrangement Performed for Others, Reimbursement for Costs Incurred, Percent + References No definition available. + Details
Name: | exel_ResearchandDevelopmentArrangementPerformedforOthersReimbursementforCostsIncurredPercent
Namespace Prefix: | exel_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Royalty Tier + References No definition available. + Details
Name: | exel_RoyaltyTier
Namespace Prefix: | exel_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Upfront Payment(s) + References No definition available. + Details
Name: | exel_UpfrontPayments
Namespace Prefix: | exel_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time, classified as current. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 45 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=82913815&loc=SL49130531-203044 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 45 -Paragraph 3 -URI http://asc.fasb.org/extlink&oid=82913815&loc=SL49130533-203044 + Details
Name: | us-gaap_ContractWithCustomerAssetNetCurrent
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Revenue earned during the period relating to consideration received from another party for the right to use, but not own, certain of the entity's intangible assets. Licensing arrangements include, but are not limited to, rights to use a patent, copyright, technology, manufacturing process, software or trademark. Licensing fees are generally, but not always, fixed as to amount and not dependent upon the revenue generated by the licensing party. An entity may receive licensing fees for licenses that also generate royalty payments to the entity. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 225 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.1(e)) -URI http://asc.fasb.org/extlink&oid=63488584&loc=d3e20235-122688 + Details
Name: | us-gaap_LicensesRevenue
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Amount of transaction price allocated to performance obligation that has not been recognized as revenue. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 270 -SubTopic 10 -Section 50 -Paragraph 1A -Subparagraph (e) -URI http://asc.fasb.org/extlink&oid=84173487&loc=SL51747714-108306 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 13 -Subparagraph (b)(1) -URI http://asc.fasb.org/extlink&oid=82913847&loc=SL49130556-203045 + Details
Name: | us-gaap_RevenueRemainingPerformanceObligation
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithIpsenMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_MajorCustomersAxis=exel_GlaxoSmithKlineMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | exel_RoyaltytierAxis=exel_FinalTierMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_RangeAxis=us-gaap_MinimumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_RangeAxis=us-gaap_MaximumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | exel_RoyaltytierAxis=exel_InitialMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | exel_RoyaltytierAxis=exel_SecondMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | exel_MilestoneObjectiveAxis=exel_EMAFilingAcceptanceHCCMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | exel_MilestoneObjectiveAxis=exel_EMAApprovalHCCMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | exel_MilestoneObjectiveAxis=exel_EMAApproval1LRCCMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |